Stock AnalizSupernus, Inc. SUPN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Supernus, Inc. (SUPN) is a healthcare company listed in the US with a market value of about $6.2B. In the twelve months to September 30, 2026 it had revenue of $1.4B and net income of $450M, a net margin of 32.8%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (1/5).
Key numbers: a P/E of 13.7, a price to free cash flow of 199.1, a 5-year average ROIC of 24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 218% above the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Positive free cash flow
Checks not passed
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.2B | $1.2B | $1.1B | $901M | $791M |
| Net income | $450M | $210M | $7M | -$126M | -$44M | $205M |
| Free cash flow | $31M | -$93M | $7M | -$308M | -$9M | $349M |
| EPS (diluted) | $2.17 | $1.01 | $0.03 | $-0.61 | $-0.21 | $0.99 |
| Net margin | 32.8% | 17.0% | 0.6% | -11.5% | -4.9% | 25.9% |
| ROIC | — | 91.0% | 79.0% | -77.7% | -13.2% | 38.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $54.14, 82% above the current price; targets range from $45.00 to $87.00; the consensus rating is “Strong buy”; expected EPS is $3.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Supernus’s P/E ratio?
About 13.7, based on the last twelve months of diluted earnings per share (forward P/E about 7.7).
Is Supernus stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 218% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Supernus pay a dividend?
Not currently.
Is Supernus a good stock to buy?
We do not give buy or sell advice. Supernus scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.